in combination with nivolumab in pts with melanoma who progressed during prior anti-PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations. Annals of Oncology. 2017;28:v611
29. Allison J. Immune Checkpoint Blockade in Cancer Therapy: New insights into therapeutic mechanisms of anti-CTLA4 and anti-PD-1. SITC 2020. 31. Joyce P. Immunopeptidome Changes Mediated by a Novel ERAP1 Inhibitor Leads to Tumor Growth Inhibition. SITC2020. 32. Morris Z. The Immuno-Radiobi...
NilotinibAnti-PDL1 therapyMHC-ICD8+T cellAlthough immune checkpoint inhibitors (ICIs) have revolutionized the landscape of cancer treatment, only a minority of colorectal cancer (CRC) patients respond to them. Enhancing tumor immunogenicity by increasing major histocompatibility complex I (MHC-I) ...
Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell death protein 1 or its ligand 1 (anti-PD-(L)1),
However, only a small proportion of NSCLC patients responded to monotherapy of anti-PD-1/PDL1 agents; together, the development of resistance to anti-PD-1/PD-L1 therapy that leads to failure of anti-PD-1/PD-L1 therapy has significantly limited a broad applicability of the findings in ...
Programmed cell death 1 ligand 1 (PDL1)/programmed cell death 1 (PD1) blockade immunotherapy provides a prospective strategy for the treatment of colorectal cancer (CRC), but various constraints on the effectiveness of the treatment are still remaining.
(DC1) could improve checkpoint therapy in a preclinical model of HER2+ breast cancer. TUBO bearing mice were vaccinated with either MHC class I or class II HER2 peptide pulsed DC1 (class I or class II HER2-DC1) concurrently or sequentially with administration of anti-PD-1 or anti-PDL1. ...
Recent data suggest that inducible PD-L1 expression may be most important for responses to PD-1 blockade therapy. In this scenario, the pre-existing presence of PD-1-positive T cells with tumour antigen specificity, which became inactivated upon PD-L1 engagement, is required for antitumour respo...
Anti-PD-1 therapy can provide long, durable benefit to a fraction of patients. The on-label PD-L1 test, however, does not accurately predict response. To build a better biomarker, we created a method called T Cell Subtype Profiling (TCSP) that characteri
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy In this study we set out to investigate whether anti PDL1 or PD鈥 1 treatment targeting the immune system could be used against multiple myeloma. DCs are important in regulat...